Systematic review with meta‐analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials | Zendy

Cholapranee A. | Zendy; Hazlewood G. S | Zendy; Kaplan G. G. | Zendy; PeyrinBiroulet L. | Zendy; Ananthakrishnan A. N. | Zendy

Premium

Systematic review with meta‐analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials

Author(s) -

Cholapranee A.,

Hazlewood G. S,

Kaplan G. G.,

PeyrinBiroulet L.,

Ananthakrishnan A. N.

Publication year - 2017

Publication title -

alimentary pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.308

H-Index - 177

eISSN - 1365-2036

pISSN - 0269-2813

DOI - 10.1111/apt.14030

Subject(s) - medicine , infliximab , ulcerative colitis , maintenance therapy , azathioprine , placebo , gastroenterology , crohn's disease , randomized controlled trial , adalimumab , odds ratio , vedolizumab , meta analysis , clinical endpoint , surgery , disease , pathology , chemotherapy , alternative medicine

Summary Background Mucosal healing is an important therapeutic endpoint in the management of Crohn's disease ( CD ) and ulcerative colitis ( UC ). Limited data exist regarding the comparative efficacy of various therapies in achieving this outcome. Aim To perform a systematic review and meta‐analysis of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis. Methods We performed a systematic review and meta‐analysis of randomised controlled trials ( RCT ) examining mucosal healing as an endpoint of immunosuppressives, anti‐tumour necrosis factor α (anti‐ TNF ) or anti‐integrin monoclonal antibody therapy for moderate‐to‐severe CD or UC . Pooled effect sizes for induction and maintenance of mucosal healing were calculated and pairwise treatment comparisons evaluated using a Bayesian network meta‐analysis. Results A total of 12 RCT s were included in the meta‐analysis ( CD – 2 induction, 4 maintenance; UC – 8 induction, 5 maintenance). Duration of follow‐up was 6–12 weeks for induction and 32‐54 weeks for maintenance trials. In CD , anti‐ TNF s were more effective than placebo for maintaining mucosal healing [28% vs. 1%, Odds ratio ( OR ) 19.71, 95% confidence interval ( CI ) 3.51–110.84]. In UC , anti‐ TNF s and anti‐integrins were more effective than placebo for inducing (45% vs. 30%) and maintaining mucosal healing (33% vs. 18%). In network analysis, adalimumab therapy was inferior to infliximab [ OR 0.45, 95% credible interval (CrI) 0.25–0.82] and combination infliximab‐azathioprine ( OR 0.32, 95% CrI 0.12–0.84) for inducing mucosal healing in UC . There was no statistically significant pairwise difference between vedolizumab and anti‐ TNF agents in UC . Conclusions Anti‐ TNF and anti‐integrin biological agents are effective in inducing mucosal healing in UC , with adalimumab being inferior to infliximab or combination therapy. Infliximab and adalimumab were similar in CD .

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research